gilead is committed to ensuring that a drug's price is never a barrier to access. we support a number of programs that help ensure patients who need our therapies have access to them.
Keywords to Search:
Company Address:
333 Lakeside Dr,FOSTER CITY,CA,USA
ZIP Code: Postal Code:
94404-1147
Telephone Number:
6505789264 (+1-650-578-9264)
Fax Number:
6505743000 (+1-650-574-3000)
Website:
www. gilead. com
Email:
USA SIC Code(Standard Industrial Classification Code):
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Gilead Sciences Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
Gilead Sciences: Company Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
Gilead Sciences Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need
Gilead Sciences Announces First Quarter 2025 Financial Results FOSTER CITY, Calif -- (BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) announced today its first quarter 2025 results of operations “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
Gilead and Xilio Announce Exclusive License Agreement . . . - Gilead Sciences FOSTER CITY, Calif WALTHAM, Mass -- (BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) and Xilio Therapeutics, Inc (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301
Gilead Sciences, Inc. - Investor Relations At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
Gilead Sciences Announces Completion of Acquisition of CymaBay FOSTER CITY, Calif -- (BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc (Nasdaq: CBAY) for approximately $4 3 billion in total equity value
Pursuing Advances in Research at Gilead Sciences Gilead Sciences advances world-class research that generates transformative medicines to address critical needs across virology, oncology inflammation